
Overdose deaths decline, a cross-species kidney transplant, poems help conservation efforts: Catch up on the day's stories
👋 Welcome to 5 Things PM! Do you consistently clock in overtime? Working long hours could come with a cost. Along with physical and emotional overexertion, new research found 'significant changes' in the brains of people who are overworked.
Here's what else you might have missed during your busy day:
1️⃣ Unprecedented drop: US drug overdose deaths in 2024 hit the lowest they've been in five years, according to a new estimate from the federal government. Last month, the Trump administration laid out its drug policy priorities for 2025, but cuts to funding for agencies like the CDC could threaten the progress made.
2️⃣ Costs an arm and a leg: Home-renovation professionals tell CNN that they've been bracing for higher prices due to tariffs. From Tuscan tilework to Chinese refrigerators, the US imports billions of dollars worth of home goods from around the globe. Here's how tariffs are threatening this booming industry.
3️⃣ A shot at living: In the US, nearly 90,000 people are on the waiting list for a kidney transplant. The typical wait is three to five years, but that time was doubled for Tim Andrews, who also has a rare blood type. Now, Andrews is thriving as one of only a handful of patients to undergo an experimental cross-species transplant of a kidney from a genetically modified pig.
4️⃣ Poems & porpoises: The Yangtze finless porpoise — a smaller dolphin-like creature — has faced extreme declines in numbers in the past four decades. A research team in China used ancient poems to find clues as to where the animals historically thrived, to help with conservation efforts.
5️⃣ 'A magical place': This extraordinary desert country aims to be a major tourist destination by 2030. In January 2023, its government introduced changes, making a once-challenging-to-obtain visa guaranteed upon arrival after paying fees. As a result, tourism has significantly increased.
GET '5 THINGS' IN YOUR INBOX
CNN's 5 Things newsletter is your one-stop shop for the latest headlines and fascinating stories to start and end your busy day. Sign up here. ⌚Tiny time: The world's thinnest tourbillon watch — which costs $678,000 — weighs just 43 grams and squeezes intricate mechanisms into a timepiece only 1.85mm thick.
• Trump's embrace of Syria could reshape the Middle East• First on CNN: New book reveals how Biden's inner circle kept Cabinet from him in final two years of presidency• Defense cross-examination of Cassie Ventura will begin Thursday in Sean 'Diddy' Combs' trial
🍟 That's how many people McDonald's says it plans to hire this summer. It's the fast-food chain's biggest employment initiative in five years.
☠️ Fossil find: A cicada pressed into rocks approximately 47 million years ago is so well preserved that you can see the veins in its wings. The discovery gives scientists new hints about how the bug evolved.
🎤 Speaking out: Robert De Niro used his acceptance speech at the Cannes Film Festival to criticize President Donald Trump, calling him a 'philistine president.'
📺 What did ESPN name its new flagship streaming service?A. Disney+ SportsB. Sports on DemandC. ESPND. Sports Now⬇️ Scroll down for the answer.
🤩 Surprise! Celine Dion made an unexpected video appearance at Eurovision, 37 years after winning the contest. The Canadian-born star delivered a heartfelt message to contestants, organizers and viewers at the semi-final event.
👋 We'll see you tomorrow.🧠 Quiz answer: C. ESPN. 'There's power in our name, and there's trust in our name,' network chairman James Pitaro said on the decision to stick with the company's four letters.📧 Check out all of CNN's newsletters.
5 Things PM is produced by CNN's Chris Good, Meghan Pryce and Kimberly Richardson.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
NIH scientists condemn Trump research cuts
Hundreds of staffers from across the National Institutes of Health (NIH) are speaking out against the politicization of their research and termination of their work while demanding that the drastic changes made at the agency be walked back. In a letter addressed to NIH Director Jay Bhattacharya, more than 2,000 signatories stated, 'we dissent to Administration policies that undermine the NIH mission, waste public resources, and harm the health of Americans and people across the globe.' The letter was titled 'The Bethesda Declaration' in reference to where NIH's campus is located. The signatories cited Bhattacharya's stated commitment to academic freedom that he made in April and called on him to push back against the changes Trump administration has implemented at NIH under his leadership. 'Academic freedom should not be applied selectively based on political ideology. To achieve political aims, NIH has targeted multiple universities with indiscriminate grant terminations, payment freezes for ongoing research, and blanket holds on awards regardless of the quality, progress, or impact of the science,' they wrote. They pointed to U.S. law and prior research that has shown that the participation of diverse populations in studies is necessary for NIH's work. The NIH staffers further blasted the canceling of nearly completed studies. 'Ending a $5 million research study when it is 80% complete does not save $1 million, it wastes $4 million,' they wrote. The researchers called on Bhattacharya to restore foreign collaborations with the global scientific community, put independent peer reviews back in place, bring back terminated NIH staffers and rethink the 15 percent cap on indirect study costs that the Trump administration enacted. 'Combined, these actions have resulted in an unprecedented reduction in NIH spending that does not reflect efficiency but rather a dramatic reduction in life-saving research,' they stated. 'Some may use the false impression that NIH funding is not needed to justify the draconian cuts proposed in the President's Budget. This spending slowdown reflects a failure of your legal duty to use congressionally-appropriated funds for critical NIH research.' NIH research is not solely centered in Bethesda. The agency is responsible for funding research projects across the country and abroad. Numerous lawsuits have been filed to combat the pulling back of billions of dollars in NIH funding. Last week, a federal judge allowed a suit filed by university researchers and public health groups challenging the cuts to move forward. Bhattacharya responded to the letter on the social media platform X. 'We all want @NIH to succeed and I believe that dissent in science is productive. However, the Bethesda Declaration has some fundamental misconceptions about the policy directions NIH has taken in recent months,' he wrote. Bhattacharya said the actions taken at NIH have been to 'remove ideological influence from science' and further argued the agency hasn't halted international scientific collaboration but is instead 'ensuring accountability.' 'Claims that NIH is undermining peer review are misunderstood. We're expanding access to publishing while strengthening transparency, rigor, and reproducibility in NIH-funded research,' he wrote. 'Lastly, we are reviewing each termination case carefully and some individuals have already been reinstated. As NIH priorities evolve, so must our staffing to stay mission-focused and responsibly manage taxpayer dollars.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
41 minutes ago
- Yahoo
Why Universal Health Services (UHS) Shares Are Trading Lower Today
Shares of hospital management company Universal Health Services (NYSE:UHS) fell 5.7% in the afternoon session after Chief Financial Officer Steve Filton noted during a recent conference that procedural volumes (an important driver of hospital revenue) "have been slower to recover back to historical levels than we might have imagined." Filton also voiced concern over the Trump administration's proposed federal spending bill, particularly its implications for healthcare funding. Since UHS derives a significant portion of its revenue from government programs like Medicare and Medicaid, the anticipated cuts to Medicaid could significantly affect the company, especially in regions with high dependency on public healthcare funding. The shares closed the day at $177.76, down 6.2% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Universal Health Services? Access our full analysis report here, it's free. Universal Health Services's shares are not very volatile and have only had 8 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 28 days ago when the stock gained 5.9% after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains. However, President Trump clarified that tariffs could go "substantially higher" if a full deal with China wasn't reached during the 90-day pause, but not all the way back to the previous levels. Still, the agreement has cooled fears of a prolonged trade war, helping stabilize expectations for global growth and trade flows and fueling renewed optimism. The optimism appeared concentrated in key trade-sensitive sectors, particularly technology, retail, and industrials, as lower tariffs reduce cost pressures and restore cross-border demand. Universal Health Services is down 1.1% since the beginning of the year, and at $177.77 per share, it is trading 26.4% below its 52-week high of $241.52 from September 2024. Investors who bought $1,000 worth of Universal Health Services's shares 5 years ago would now be looking at an investment worth $1,628. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
No drug price pledges in talks with US government, Pfizer CEO says
STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made. He made the comments at a Goldman Sachs healthcare conference. Last month President Trump issued an executive order directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "Most Favored Nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Bourla said he didn't know what the companies would hear in 30 days and added the meetings with the administration so far were cordial but (quote) "not digging into the substance." It is unclear what mechanism the U.S. government will use to lower drug prices - analysts and legal experts have said the policy will be difficult to implement. Bourla said he is hopeful that, given U.S. pressure on European countries to pay more, prices there could increase. He said that if the U.S. resorts to price controls, Pfizer could consider not making drugs available for government reimbursement in some countries if prices don't increase there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data